Terms: = Endocrine gland cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA AND Treatment
24 results:
1. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
2. Pancreatic cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic cancer.
Abdilleh K; Khalid O; Ladnier D; Wan W; Seepo S; Rupp G; Corelj V; Worman ZF; Sain D; DiGiovanna J; Press B; Chandrashekhar S; Collisson E; Cui KY; Maitra A; Rejto PA; White KP; Matrisian L; Doss S
JCO Clin Cancer Inform; 2024 Jan; 8():e2300119. PubMed ID: 38166233
[TBL] [Abstract] [Full Text] [Related]
3. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract] [Full Text] [Related]
4. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
5. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract] [Full Text] [Related]
6. The potential targeted drugs for fusion genes including nrg1 in pancreatic cancer.
Umemoto K; Sunakawa Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
[TBL] [Abstract] [Full Text] [Related]
7. [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
Schlitter AM; Konukiewitz B; Kasajima A; Reichert M; Klöppel G
Pathologe; 2021 Sep; 42(5):464-471. PubMed ID: 34402977
[TBL] [Abstract] [Full Text] [Related]
8. Early-Onset Pancreas cancer: Clinical Descriptors, Genomics, and Outcomes.
Varghese AM; Singh I; Singh R; Kunte S; Chou JF; Capanu M; Wong W; Lowery MA; Stadler ZK; Salo-Mullen E; Saadat LV; Wei AC; Reyngold M; Basturk O; Benayed R; Mandelker D; Iacobuzio-Donahue CA; Kelsen DP; Park W; Yu KH; O'Reilly EM
J Natl Cancer Inst; 2021 Sep; 113(9):1194-1202. PubMed ID: 33755158
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data.
Grogg JB; Fronzaroli JN; Oliveira P; Bode PK; Lorch A; Issa A; Beyer J; Eberli D; Sangar V; Hermanns T; Clarke NW; Fankhauser CD
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2671-2679. PubMed ID: 33559739
[TBL] [Abstract] [Full Text] [Related]
10. Clinical perspectives of BET inhibition in ovarian cancer.
Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Cell Oncol (Dordr); 2021 Apr; 44(2):237-249. PubMed ID: 33469840
[TBL] [Abstract] [Full Text] [Related]
11. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract] [Full Text] [Related]
12. How I treat pancreatic cancer.
Taieb J; Abdallah R
ESMO Open; 2020 Aug; 4(Suppl 2):e000818. PubMed ID: 32817138
[TBL] [Abstract] [Full Text] [Related]
13. nrg1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract] [Full Text] [Related]
14. Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients.
Zheng H; Zhang M; Ma S; Yang W; Xie S; Wang Y; Liu Y; Kai J; Ma Q; Lu R; Guo L
Cancer Med; 2020 Jul; 9(14):5200-5209. PubMed ID: 32441484
[TBL] [Abstract] [Full Text] [Related]
15. Oncogenic nrg1 Fusions: A New Hope for Targeted Therapy in Pancreatic cancer.
Aguirre AJ
Clin Cancer Res; 2019 Aug; 25(15):4589-4591. PubMed ID: 31164372
[TBL] [Abstract] [Full Text] [Related]
16.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract] [Full Text] [Related]
17. nrg1 regulates redox homeostasis via NRF2 in papillary thyroid cancer.
Zhang TT; Qu N; Sun GH; Zhang L; Wang YJ; Mu XM; Wei WJ; Wang YL; Wang Y; Ji QH; Zhu YX; Shi RL
Int J Oncol; 2018 Aug; 53(2):685-693. PubMed ID: 29901070
[TBL] [Abstract] [Full Text] [Related]
18.
Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
[TBL] [Abstract] [Full Text] [Related]
19. Are pitch and roll compensations required in all pathologies? A data analysis of 2945 fractions.
Mancosu P; Reggiori G; Gaudino A; Lobefalo F; Paganini L; Palumbo V; Stravato A; Tomatis S; Scorsetti M
Br J Radiol; 2015; 88(1055):20150468. PubMed ID: 26393283
[TBL] [Abstract] [Full Text] [Related]
20. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
Paul BT; Blanchard Z; Ridgway M; ElShamy WM
Oncogene; 2015 Jun; 34(23):3036-52. PubMed ID: 25132263
[TBL] [Abstract] [Full Text] [Related]
[Next]
